Takashi Futamura
Tokushima, 7710192, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 24 publications
Clozapine disrupts the gut-lung microbiota axis, linking gastrointestinal hypomotility to increased respiratory vulnerability.
Journal: Translational psychiatry
Published: January 17, 2026
Synergistic Effect of Combination Treatment of Brexpiprazole and Nalmefene on Ethanol Intake in Rats.
Journal: Neuropsychopharmacology reports
Published: June 06, 2025
Brexpiprazole: A new option in treating agitation in Alzheimer's dementia-Insights from transgenic mouse models.
Journal: Neuropsychopharmacology reports
Published: April 24, 2024
Synergistic anti-depressive effect of combination treatment of Brexpiprazole and selective serotonin reuptake inhibitors on forced swimming test in mice.
Journal: Neuropsychopharmacology reports
Published: October 28, 2022
Fragment-Based Discovery of a Novel, Brain Penetrant, Orally Active HDAC2 Inhibitor.
Journal: ACS medicinal chemistry letters
Published: June 07, 2022
Chronic social defeat stress increases the amounts of 12-lipoxygenase lipid metabolites in the nucleus accumbens of stress-resilient mice.
Journal: Scientific reports
Published: May 10, 2022
Prenatal methotrexate injection increases behaviors possibly associated with depression and/or autism in rat offspring; A new animal model for mental disorder, based on folate metabolism deficit during pregnancy.
Journal: Neuropsychopharmacology reports
Published: February 10, 2022
Discovery research and development history of the dopamine D2 receptor partial agonists, aripiprazole and brexpiprazole.
Journal: Neuropsychopharmacology reports
Published: March 08, 2021
Preclinical pharmacological profiles and clinical efficacy of the novel antipsychotic drug brexpiprazole (REXULTI® Tablets 1 mg, 2 mg)
Journal: Nihon yakurigaku zasshi. Folia pharmacologica Japonica
Published: November 19, 2019
Brexpiprazole has a low risk of dopamine D2 receptor sensitization and inhibits rebound phenomena related to D2 and serotonin 5-HT2A receptors in rats.
Journal: Neuropsychopharmacology reports
Published: June 05, 2019
Increased BDNF-TrkB signaling in the nucleus accumbens plays a role in the risk for psychosis after cannabis exposure during adolescence.
Journal: Pharmacology, biochemistry, and behavior
Published: December 18, 2018
Alterations in amino acid levels in mouse brain regions after adjunctive treatment of brexpiprazole with fluoxetine: comparison with (R)-ketamine.
Journal: Psychopharmacology
Published: April 11, 2017
Last Updated: 09/26/2026